the tissue. In two cases, information on the site was missing. The pretreatment characteristics of the patients in this study are shown in Table 2 .
The Helsinki STS group is a member of the Scandinavian Sarcoma Group (SSG), in which a four-grade histological malignancy grading system is applied. For the grading, the combination of the histological type and a combination of histopathological parameters, which include necrosis, vascular invasion, cellularity, mitotic activity and nuclear pleomorphism, is used. Since the publication of our study on SPF , the histopathological subtypes have been changed in seven cases during the peer review sessions by the SSG pathologists.
The median follow-up time of living patients (n = 71) was 72 months (range 22-447 months). Four patients have died without disease. Fifty-one patients developed metastasis, nine of them are living.
In the statistical analysis, we stratified the cases according to genetic classification. We separated tumours known to have common specific chromosomal changes, e.g. synovial sarcomas, extraskeletal Ewing's sarcoma, myxoid liposarcoma and round cell liposarcoma. The remaining cases formed a mixed group, of which the largest proportion were pleomorphic sarcomas. Table 2 shows the stratification. Three sarcomas with specific chromosomal changes were included in the miscellaneous sarcoma group because they were single cases of alveolar rhabdomyosarcoma, extraskeletal myxoid chondrosarcoma and clear cell sarcoma (Fletcher, 1995; Sheer, 1997) .
Methods
Several different antibodies detect the same large nuclear active phase protein . In this study, we used the monoclonal Mib-1 antibody, which reacts with Ki-67 in formalin-fixed archival material.
The samples were deparaffinated in xylene and rehydrated in alcohol to distilled water. Antigen demasking was carried out by heating the samples in a microwave oven (850 W) in citric acid buffer (pH 6, 0.1 M) four times for 5 min. Metanol peroxidase (1.6%) was used to inhibit the endogenous peroxidase activity of the sample. Ki-67 staining was carried out by mouse anti-human monoclonal Mib-1 antibody (PharMingen). Our antibody dilution was 1:500, and we incubated samples overnight at room temperature. To reveal the binding of the primary antibody by peroxidase staining, we used the Vectastain ABC kit (Vector Laboratories). Haematoxylin was used for background staining.
When evaluating the results of the immunostaining, we chose the tumour area with the highest density of positive nuclear staining. A magnification of 10 × 40 was used. The percentage of positively stained nuclei was evaluated with an ocular grid of 100 (10 × 10) squares. We counted all the positive nuclei from this area. To estimate the negative nuclei in the same area of 100 squares, we counted three different rows of ten squares and multiplied the mean of the results by ten. The percentage of positive nuclei was counted by dividing the positive stained cells by the entire number of cells in the same area. In the case of tumours with scarce cellularity, several fields were evaluated, and negative nuclei were counted from the whole grid area of 100 squares. All samples were scored by two independent observers (RH and TB). When the interobserver difference in the result was greater than 5%, the sample was rescored by the two investigators together.
A modification of the basic Hedley method was used in flow cytometric measurements (Hedley, 1989; Heiden et al, 1991) . The sections (100 µm) from the paraffin blocks were placed in finemesh bags which were inserted into cassettes and then dewaxed and rehydrated in a tissue processor. Enzymatic digestion was carried out with Subtilisin Carlsberg (Sigma Protease type 24) and all centrifugation steps were omitted, resulting in nuclei suspensions with extremely low amounts of clumped nuclei and debris. The nuclei were stained with DAPI (final concentration 5 µM) and analysed using a PAS 2 flow cytometer. To confirm the ploidy of near-diploid populations, the DNA content of the identified nuclei was measured by means of a static image analysis system. Tumours were considered diploid if only one G1 peak was present. For determination of the DNA index in grossly aneuploid cell populations, the first peak to the left was assumed to represent diploid cells. For the determination of the percentage of cells in the S-phase of the cell cycle, the MultiCycle program with the slicednuclei option for background subtraction, developed by Rabinowich, was used (Phoenix Flow System, San Diego, CA, USA). Flow cytometry measurements were carried out at the Radiobiological Department of the Karolinska Institute in Stockholm .
Statistical methods
Survival analyses were carried out with the Macintosh SPSS computer program, and all other analyses with the Macintosh Statistica program. The correlations between different variables, except ploidy, were calculated with the Spearman rank order correlation test. The confidence intervals of the Spearman rank Table 1 Histology and grade of the missing samples and the unsuccessful Ki-67 stainings
Histology
Missing samples, n Unsuccessful staining, n Malignant fibrous histiocytoma 4 (G3 = 3, G4 = 1) a 1 (G4 = 1) Leiomyosarcoma 2 (G1 = 1, G3 = 1) 4 (G1 = 1, G3 = 2, G4 = 1) Synovial sarcoma 1 (G3 = 1) 1 (G3 = 1) Extraskeletal Ewing's sarcoma 2 (G4 = 2) Epithelioid sarcoma 1 (G3 = 1) Liposarcoma 2 (G1 = 2) Extraskeletal osteosarcoma 2 (G3 = 1, G4 = 1) Unclassified sarcoma 1 (G4 = 1) Fibrosarcoma 1 (G1 = 1) a G1-G4 = number of patients with grade 1-4 tumours.
order correlation test were calculated according to Altman (1994) . The correlation between ploidy and Ki-67 was calculated with the Mann-Whitney U-test. Analyses of disease-specific overall survival (DSOS) and metastasis-free survival (MFS) were carried out using the Cox regression model. In the Cox regression model analysis, Ki-67 and SPF were continuous variables. The prognostic value of the different cut-off points of Ki-67 and SPF was further investigated by dividing the material into two by 10% percentiles (i.e. cut-off points defining 10% of the patients in the low-risk and 90% in the high-risk group, 20% in the low-risk and 80% in the high-risk group, etc.). The corresponding cut-off values for Ki-67 and SPF are shown in Figure 1 . For each cut-off point, the relative risk of death or distant relapse and 95% confidence levels were calculated by Cox regression analysis.
Survival curves were calculated by using the cut-point value of 10% for Ki-67, the value with the greatest discriminative power in the study of Choong et al (1994) . Thirty-four (28%) patients had tumours with equal or lower Ki-67 value than 10%. In the group of miscellaneous sarcomas, 18 (19%) tumours of 94 cases were below this limit. To compare the results with SPF, we chose the cut-off point of 3.9% for SPF, which divided the material similarly to the Ki-67 cut-off point of 10% (i.e. 28% had equal or lower values of SPF). The survival curves have been calculated by the Kaplan-Meier method (Figures 2 and 3) .
RESULTS
The median value of Ki-67 was 18% (range 1-55%). The median of Ki-67 was highest in malignant fibrous histiocytomas and lowest in liposarcomas. Low-grade tumours had a lower median of Ki-67 than high-grade tumours. The medians and ranges of Ki-67 and SPF by grade, histotype and genetic class are shown in Table 3 .
The Ki-67 staining score was strongly correlated with histological grade (P < 0.001), ploidy (P < 0.001) and SPF [r s (±95%CI) = 0.57 (0.44-0.68), P < 0.001]. There was no correlation between Ki-67 and tumour size (P = 0.2), or SPF and size (P = 0.16). SPF correlated with grade and ploidy (P < 0.001 both). The correlations between Ki-67 and SPF are shown in Figure 4 , with diploid and non-diploid tumours presented separately. Histology Malignant fibrous histiocytoma a (G2 = 4, G3 = 14, G4 = 16) b 34 28 Liposarcoma c (G1 = 2, G2 = 8, G3 = 2, G4 = 3) 15 12 Leiomyosarcoma (G1 = 2, G2 = 2, G3 = 5, G4 = 2) 11 9 Synovial sarcoma (G2 = 1, G3 = 9, G4 = 2) 12 10 Extraskeletal Ewing's sarcoma (G3 = 1, G4 = 7) 8 6 Fibrosarcoma (G1 = 1, G2 = 4, G3 = 2) 7 6 Malignant Schwannoma (G2 = 1, G3 = 2, G4 = 2) 5 4 Unclassified sarcoma (G1 = 1, G2 = 2, G3 = 8, G4 = 8) 19 15 Other sarcoma d (G2 = 4, G3 = 3, G4 = 3) 12 10
Histological grouping by known chromosomal changes n (diploid n) Miscellaneous sarcoma 94 (34) 76 Synovial sarcoma 12 (11) 10 Myxoid liposarcoma and round cell liposarcoma 9 (7) 7 Extraskeletal Ewing's sarcoma 8 (7) 7 a Storiform-pleomorphic n = 27, myxoid n = 7; b G1-G4 = number of patients with grade 1-4 tumours; c well-differentiated n = 2, myxoid n = 8, round cell n = 1, pleomorphic n = 3, pleomorphic-storiform n = 1; d myxofibrosarcoma n = 1, extraskeletal myxoid chondrosarcoma n = 1, clear cell sarcoma n = 1, alveolar rhabdomyosarcoma n = 1, malignant haemangiopericytoma n = 1, stromal sarcoma n = 1, angiosarcoma n = 2, epithelioid sarcoma n = 2, extraskeletal osteosarcoma n = 2. When analysed as a continuous variable, Ki-67 was a stronger predictor of both MFS and DSOS (P = 0.003 and P = 0.04 respectively) than SPF (P = 0.06 and 0.07 respectively). When using cutoff points of 10% for Ki-67, it predicted MFS and DSOS (P = 0.02 and P = 0.02 respectively). When using a cut-off point of 3.9% for SPF, it predicted MFS and DSOS (P = 0.03 and P = 0.003 respectively). The estimated 5 years of MFS was 79% for tumours with Ki-67 ≤ 10% and 57% for tumours with Ki-67 > 10%. The estimated 5 years of DSOS was 82% for tumours with Ki-6 ≤ 10% and 60% for tumours with Ki-67 > 10%. The estimated 5 years of MFS was 81% for tumours with SPF ≤ 3.9% and 57% for tumours with SPF > 3.9%. The estimated 5 years of DSOS was 90% for tumours with SPF ≤ 3.9% and 57% for tumours with SPF > 3.9%. But when analysed separately in diploid and non-diploid tumour groups, SPF cut-point of 3.9 predicted DSOS only in diploid tumours and not in non-diploid tumours (P = 0.02 and P = 0.02 respectively). MFS and DSOS in the four genetic groups, according to the cut-off points of 10% for Ki-67 and 3.9% for the SPF, are shown in Figures 2 and 3 . Analysed in this way, Ki-67 was of significant prognostic value only in the group of miscellaneous sarcomas (P-value for MFS <0.001 and P-value for DSOS = 0.01). Figure 4 gives the discriminative values of Ki-67 and SPF for MFS and DSOS as a function of various cut-off points by relative risk and confidence interval. 
DISCUSSION
The results of our study are in accordance with previous findings (Table 4) , which indicate that Ki-67 is of prognostic value in STS. Compared with SPF, Ki-67 seemed to be a stronger prognostic factor. Ki-67 measurements are also more economical and easier to perform than SPF measurements. When comparing the discriminative values of different cut-off points, it became evident that the weaker prognostic effect of SPF seems to be due to the poor discriminative power of high SPF values. With low cut-off points, SPF seemed to be an equally effective prognostic factor as Ki-67, which is in accordance with previous results (Collin et al, 1997; Gustafson et al, 1997) . The results of Gustafson and of Collin are not directly comparable to ours, however, because both of these investigators excluded 35-37% of their tumours because of uninterpretable histograms. The majority of the excluded cases were non-diploid. Because of differences in techniques, we were able to calculate the SPF also in the majority of cases with non-diploid tumours. These histograms, nevertheless, did not add much to the prognostic value of SPF because SPF failed to be of prognostic value in non-diploid tumours, as shown previously .
Thus, in contrast to SPF, our results indicate that Ki-67 can be utilized to define a small group of patients with a high risk of relapse, whereas SPF and Ki-67 seemed equivalent in their ability to define a low-risk group. We can only speculate about why the highest SPF values fail to have prognostic implication. Because the SPF is a static rather than a dynamic proliferation parameter, a high value is not necessarily the result of a high proportion of cycling cells. A prolonged duration of the SPF, for example due to a highly disorganized genome, will also result in a high SPF. Our previously published result, i.e. that SPF is a statistically significant prognostic variable in diploid but not in non-diploid sarcomas, could thus support this hypothesis.
One difficulty in trying to find prognostic indicators for STS is the extreme heterogeneity of this group of tumours. Although many similarities in behaviour between different histotypes can be found, for example the propensity to blood-borne metastasis vs. lymphatic spread and the tendency to respect anatomical barriers in their growth, many entities still have distinct features. Especially sarcomas characterized by a specific pathognomonic gene translocation such as synovial sarcoma, Ewing's sarcoma, mesenchymal chondrosarcoma and myxoid liposarcoma often display specific behaviour. Features distinguishing these entities from other STS include frequent late relapse in synovial sarcoma, myxoid liposarcoma and Ewing's sarcoma, soft-tissue metastases in myxoid liposarcoma and bone metastases in Ewing's sarcoma (Enzinger and Weiss, 1995) .
In this study, we therefore decided to stratify the cases with respect to histogenesis, with special reference to disease-specific chromosomal translocations. When we analysed the prognostic value of proliferation measured by Ki-67 in these subgroups, it appeared that the discriminative power is quite strong in the mixed group of miscellaneous, mostly pleomorphic sarcomas. There was no clear indication of prognostic value in any of the tumours characterized by specific gene translocations because these tumour groups were too small to be analysed separately. Probably, the unexpected result in the synovial sarcoma patient group, in which low proliferative activity correlated with poorer outcome, is simply coincidental. In the group of miscellaneous pleomorphic sarcomas, however, the results seem sufficiently promising to justify a large confirmatory study.
